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Effect of calcium restriction on renal excretion of oxalate and the
probability of forming stone. P. Bataille, J. L. Daigre, G. Charransol, A.
Pruna, B. Coevoet, P. Loquet, I. Gregoire, A. Fournier. CHU Amiens;
I. Hydrologie, Paris, France. To evaluate the adequacy of the usual
simple calcium restriction (Ca R) in idiopathic calcium stone-formers
(SF), the effect of a 4-day Ca R without oxalate (OX) restriction on renal
excretion of Ca and OX and the corresponding probability of being a
stone-forming patient (PSF coefficient of Robertson) was assessed in 50
controls and 48 stone-forming patients classified according to the
criteria of Pak. The results are:
Groups
Calciuria mg/day
No Ca R/With Ca R
Oxaluria mg/day
No Ca R/ With Ca R
PSF change
with Ca R
Controls (N = 50)
Normo-calciuria (N = 17)
AH II (N = II)
AH I (N = 10)
RH (N = JO)
198 122°°
210 1500*
433 1930*0
378 289**
380 3O'J0°
29 34*0
38 44***
34 44*0
40 54*0*
34 44***
+0.01
—0.02
+0.07*
+0.10*
P value of the difference * <0.05, ** <ooJ, '° <0.001
Renal excretion of Ca decreased and that of OX increased in all groups
but the degree of change was critically dependent on the underlying
pathophysiology: PSF decreased only in absorptive hypercalciuria type
II (AH II) due to usual excessive calcium intake and increased in
absorptive hypercalciuria type I (AH I) and renal hypercalciuria (RH)
which both have true hyperabsorption of calcium. In conclusion, simple
calcium restriction is beneficial for Ca SF only when they are hypercal-
ciuric because of excessive calcium intake. For the other patients, the
associated increased in oxalate excretion offsets the benefit of lowering
calcium excretion, stressing the importance of simultaneous oxalate
restriction.
Improved proteinuria with oral converting enzyme inhibitor (Capto-
pill) in renovascular hypertension. P. L. Caraman, M. Kessler, B.
Hurault de Ligny, C. Haney. Service de Néphrologie, C.H. U. de
Brabois, Vandoeuvre, France. Two cases of normalized proteinuria by
Captopril were reported in patients with renovascular hypertension.
The first has recurring hypertension 15 years after bilateral aortorenal
bypass for proximal stenosis of the two renal arteries; the aortography
shows total thrombosis of the right bypass; he presented a nephrotic
syndrome: proteinuria 3.50 g/24 hr, serum protein 53 glliter with
moderated renal failure. Blood pressure is normalized and the nephrotic
syndrome disappeared completely within a month using Captopril. The
second patient presented recurring hypertension 8 years after left
adrenalectomy for Conn's syndrome, caused by a tight proximal
stenosis of the left renal artery with significantly increased plasma renin
activity. Blood pressure was controlled with oral Captopril and protein-
uria decreased from 3.20 g/24 hr to 0.50 g/24 hr. These observations
appear to corroborate the effect of angiotensin II in the permeability of
the glomerular capillary walls to albumin. Thus, proteinuria is a biologic
marker of the efficiency and/or toxicity of the converting enzyme
inhibitor.
A new association: Ankylosing spondylitis and Berger disease. S. Dard,
A. Kanfer, S. Kenouch, L. Morel-Maroger, andJ. P. Méry, Service de
Nephrologie, Hôpital Bichat and Hôpital Tenon, Paris, France. The
association of ankylosing spondylitis and Berger disease was observed
in two patients. In patient no. I, extensively studied, the first manifesta-
tions of both ankylosing spondylitis and Berger disease (that is,
macroscopic hematuria) occurred simultaneously at the age of 15.
Berger disease was suspected at a first renal biopsy when the patient
was 20 years old. The course of both ankylosing spondylitis and Berger
disease was very severe. The patient was 29 years old when he was seen
for the first time. He had severe hypertension and renal insufficiency
(creatinine clearance of 20 mI/mn); motion of his lumbar spine and
expansion of his chest were extremely limited. A second renal biopsy
clearly confirmed the diagnostic of Berger disease. The patient's father
has also a severe ankylosing spondylitis but he has no sign of nephrop-
athy. Both have in common the haplotype A3, B27, and DR2. Another
patient's records were found. Berger disease was discovered, at age 32,
7 years after the first manifestations of ankylosing spondylitis. The course
of both articular and renal disease was benign over the 20 following years.
Three other cases of association of ankylosing spondylitis and Berger
disease were found in the literature, making a fortuitous association
mostly unlikely. Pathophysiologic hypothesis was discussed.
Urea, uric acid, and creatinine mass transfer delay in hemofiltration:
theoretical and experimental study. G. Dongradi, T. Haas, F. Ville-
boeuf, E. De Viel, J. F. Fournier, J. P. Fend/er. Poissy Hospital,
University of Paris West, Poissy, France. Solute mass transfer during
hemofiltration (HF), a potential limiting factor in high ultrafiltration rate
(UF rate) efficiency, was evaluated from a theoretical model. During
HF with specific theoretical parameters (10 constant UF rate; 2°
constant solute distribution volume, V0; 30 solute generation rate into
YD negligible compared to ultrafiltration flux; 40 no delayed solute mass
transfer from a point to another in VD), the decreasing plasma concen-
tration was an exponential curve: C = C0e° (k = membrane
transmittance coefficient for solute; -y = UF rate/VD). In experimenta-
tion with respect of conditions 1, 2, and 3, the difference between
theoretical solute mass removal (dmT) and effective solute mass remov-
al (dma) was only related to delay in solute mass transfer. Final
theoretical concentration was CT, final experiment concentration after
post HF rebound was CE: dmT = VD (C,, — CT) and dmE = V (C0 —
CE). Loss in efficiency of HF related to delayed mass transfer is (dmT —
dmE)/(dmT) = (CE — CT)/(Co — CT); C0 and CE are measured, CT is
calculated from experimental model. This calculation was made in four
patients during HF (total UF volume = 1/3 kg body weight; constant
UF rate; constant body weight and so constant Va). With UF rate of 1.5
mI/mm/kg body weight, loss of efficiency was 4% for urea and 8% for
uric acid; with UF rate of 3.0 mI/mm/kg body weight, loss of efficiency
was 6% for urea and 14% for uric acid. The calculation was not possible
for creatinine, since 2 hr post HF the concentration rebound was not
achieved; the highest post HF creatinine concentration indicated a
distribution volume expressed in equivalent-plasma volume, higher
than 85% of body weight; this value is very much higher than usual
normal values. In practice, in a patient treated by HF with a high UF
rate, the choice of the UF volume could take into account delayed
solute mass transfer.
Beneficial effect of sodium release from the cartridge in the sorbent
based dialysate regeneration system. G. Fournier, J. L. Gail/ard, N. K.
Man. Hôpital de Chartres and Hôpital Necker, Paris, France. The
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cartridge of the sorbent-based dialysate regeneration system releases
Na+ ions for K+, Ca2+, Mg2+ ions present in the dialysate and NH4+
ions generated from urea decomposition. It could be of interest to use
this extra load of sodium to increase progressively the dialysate sodium
concentration to prevent an excessive sodium loss induced by ultrafil-
tration during hemodialysis. In vitro studies showed that from an initial
100 mM Na+ dialysate, recirculating through the cartridge at a flow rate
of 200 mI/mm with a standard infusate of K+, Ca2+, and Mg2+, the
final Na+ dialysate concentration 4 hr after the start was 140 m. In the
same operating conditions, the addition of 35 g of urea in the dialysate
brought the final dialysate Na+ concentration up to 155 m instead of a
predicted value of 175 m. This suggests the interaction in the ion-
exchange process of HCO3_, which is another end product of urea
decomposition. In five patients treated with a starting dialysate Na+
concentration of 104.4 3.3 mM according to the manufacturer's
prescription (organon teknika) the mean dialysate Na+ concentration at
the end of dialysis session was 131.9 1.4 m. Plasma Na+ concentra-
tion decreased from a mean initial value of 138.8 2.1 m to a mean
final value of 135.2 1.4 m. Muscle cramps and hypotension episodes
were noted in four patients. In a second group of five patients treated
with a starting dialysate Na+ concentration of 132.0 1.8 m, the
mean dialysate Na+ concentration at the end of dialysis session was
136.2 1.6 m. Plasma Na+ concentration increased from a mean
initial value of 138.2 1.3 m to a mean final value of 142.4 0.8 mM,
that is, in the range of healthy subjects. All the patients of this group
were symptom-free during the dialysis session although the ultrafiltrate
volume was greater than that of the patient group: 3.1 0.2 liters versus
2.4 0.5 liters. A starting dialysate Na+ concentration of 130 m for
the REDY system is indicated to obtain the beneficial effect of sodium
release from the cartridge, allowing dialysis with adequate and asymp-
tomatic body weight loss.
Chronic renal failure in tuberous sclerosis (Bourneville disease). J. P.
Herve, D. Chevet, J. Cledes, P. Le Pogamp, J. P. Leroy, A. Meyrier.
Service de Nephrologie du CHU Morvan, Brest; CHU Ponchaillou,
Rennes; Hopitai Tenon, Paris, France. Kidney angiomyolipomas are
frequent in TS (tuberous sclerosis or Bourneville disease), but only 11
cases involving chronic renal failure have thus far been published. This
study reports a series of six patients, four men and two women, aged 22
to 62 years. Phakomatosis was diagnosed on the basis of family history
and the association of characteristic skin, ungual, neurologic, and
osseous lesions. The renal anomalies presented as palpable tumors and
abdominal pain in two patients, as hypertension later complicated by
pre-eclampsia in two cases; proteinuria was found in four patients and
microscopic hematuria in two patients. In three patients, the diagnosis
of TS was not made until after the onset of chronic renal failure.
Corrected creatinine clearance was 9 mI/mn in one case, between 10 to
25 mI/mn in four cases and 38 mI/mn in one case. Intravenous
pyelogram, echographic and arteriographic studies demonstrated the
characteristic images of both angiomyolipomas and occasional cysts,
except in one patient where biopsy specimens yielded segmentary and
focal hyaline glomerular lesions. In this series, followup ranged from 18
months to 6 years; renal failure increased slowly over time. One patient
died. Autopsy showed cysts associated with angiomyolipomas. Chronic
hemodialysis was initiated for another patient who later received a
successful kidney transplant after bilateral nephrectomy. These six
observations, which represent the largest known series of TS associated
with renal failure, show that the destruction of functional kidney
parenchyma is due not only to the invasion of renal parenchyma by the
hamartomas and the cysts but also to associated glomerulopathy which
may represent an unprecedented example of glomerular lesions second-
ary to hyperfiltration.
Is membranoproliferative glomerulonephritis (MPGN) disappearing in
France? P. Jungers, D. Droz, L. H. Noel, D. Fétizon, J. Mangane/la,
and J. P. Grunfeld. Clinique Néphrologique et INSERM U 25, Hôpital
Necker, Paris, France. Because a recent multicentric controlled trial
revealed an unexpected low incidence of new cases of MPGN in
France, the annual incidence of MPGN was sytematically re-evaluated
and compared with other varieties of chronic glomerulonephritis (GN)
observed at Necker Hospital throughout the last decade. Study material
included all cases of chronic GN demonstrated by renal biopsy speci-
mens in adult patients, excluding acute or rapidly progressive GN and
renal localizations of systemic diseases. All biopsies underwent light
microscopy and immunofluorescence study. Evolution of mean annual
incidence (AT) of chronic GN during three successive periods was as
follows:
Histopathological type
MPGN
1971—1974 (I)
Al %
l975
Al
—1977 (II)
%
1978—I
Al
980 (III)
%
18.2 (16.3%) 14.6 (15.3%) 6.6 (8.4%)*
(French patients only) (12.2) (9.3) (3.0)**
Membranous GN 18.0 (16.1%) 17.6 (18.3%) 20.0 (25.1%)
Berger disease 31.5 (28.2%) 30.0 (31.1%) 25.3 (31.8%)
Focal hyalinosis 18.5 (16.6%) 19.6 (20.4%) 19.0 (23.8%)
Others and unclassified 25.5 (22.8%) 14.3 (14.9%) 8.6 (10.9%)
Total GNlyear 111.7 (100 %) 96.3 (100 %) 79.7 (100 %)
Period 3 vs. 2 * < 0.02 **< 0.01
A significant decrease of the annual incidence of MPGN was observed
from period 2 to period 3, especially with regard to patients born and
living in continental France, whereas no significant difference in annual
incidence was observed in the other groups of GN. Preliminary data in
this study suggest the need for a large scale, nation-wide epidemiologic
study in adult and pediatric patients to confirm and possibly explain this
tendency.
Alterations in pharmacokinetics and ototoxicity of erythromycin (E) in
renal failure. A. Kanfer, J. P. Méry, J. C. Torlotin, and G. Fredj.
Service de Nephrologie, Hôpital Bichat, Paris, Laboratoire de Bactéri-
ologie, Hôpital Hérold, Paris and Pharmacie, Hôpital Emile-Roux,
Brévannes, France. Three patients with chronic renal failure (CRF) in
whom transient deafness occurred during (E) therapy are reported, as
well as the results of a pharmacokinetic study of (E) in CRF. The three
patients (see table) were all treated for a bacterial pneumonia and none
had a hepatic disease or had received aminosides or diuretics. In all
audiometry disclosed symmetrical perceptive deafness which predomi-
nated in the high frequencies. None had vestibular disturbances.
Hearing returned to normal within 8 to 10 days.
Patient
no. Sex
Age
years
Preat
p.molelliter
Dosage of (E)
giday—per os
Duration of treatment
before deafness occurred
days
I M 81 354 2 Ethylsuccinate 4
2 M 80 664 2.5 Ethylsuccinate 6
3 M 75 HD 3 Propionate 4
Twelve cases of transient deafness due to (E) were found in the
literature and were analyzed. Seven to ten patients in whom value of
renal function is given had either chronic (N = 5) or acute (N = 2) RF.
Daily dosage of (E) given either orally or intravenously was of 2 to 4 g.
Pharmacokinetics of (E) in patients with CRF: Eight patients on chronic
hemodialysis and ten normal controls received a single dose of I g of
ethylsuccinate of (E). Serum concentrations of (E) were assayed by a
biological method with Sarcina lutea. Both mean peak serum level of
(E) (mg/liter) and area under the curve (mg X 1 X hr) were greater in
patients than in controls: 5.08 1.1 vs. 1.65 0.2 (P <0.01) and 20.13
5.13 vs. 5.66 0.32 (P < 0.01), respectively, showing an enhanced
biodisponibility of (E) in uremic patients. In conclusion, to prevent
ototoxicity of (E) in uremic patients, it is proposed that: (1) Dosage of
(E) should not exceed 1.50 g/day in patients whose plasma creatinine is
above 180 .moles/liter; (2) (E) should not be associated with other
potentially ototoxic drugs; (3) hearing acuity should be monitored
during treatment, especially in the elderly.
Outbreak of a non-A non-B hepatitis (NANB H) epidemic in a hepatitis
B virus (HBV)-free hemodialysis (HD) unit. J. P. Méry, N. Simon, C.
Trépo, L. Vitvitski, and A. M. Couroucé. Service de Nephrologie,
Hôpital Bichat and Centre Pasreur-Vallery-Radot, Paris; INSERM
U45, Hôpital Edouard Herriot, Lyon; Centre National de Transfusion
Sanguine, Paris, France. NANB H occurred in 18 of 122 patients who
had been treated for al month in a HBV-free HD unit. Serum
transaminases (T) were determined systematically bimonthly in all
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patients. Diagnosis of NANB H was based upon: (1) elevation of T
which could not be ascribed to a drug-induced H or to a non-hepatic
disease; (2) serological exclusion of a recent infection by HBV, HBA,
CMV, and EBV. Twelve patients had received transfusions within the 6
months preceding H. NANB H was asymptomatic in 10 patients. Six
had a short and monophasic T elevation which lasted <4 months,
whereas 12 patients had a chronic H with increased and fluctuating T
for a6 months. In five of these 12 patients, T returned to normal after a
mean period of 15 months and remained normal over a mean subse-
quent period of 14 months. In the seven others, T are still increased
from 6 to 31 months after the onset of H. Serum samples, 178, were
obtained from 13 patients and tested blind by immunodiffusion for a
precipitating antigen/antibody (Ag/Ab) system held to be specific for
NANB virus. Ag was found transiently in three patients who further
sero-converted and regularly presented over a period of 4 months in one
patient. In addition, Ab was found without prior antigenemia within Ito
7 months after the onset of H in six patients and it was already present
at the first determination 2.5 months before H in one patient. HJ3IG had
a prophylactic effect against NANB H which occurred in only I of 22
patients who received HBIG during the 9 months following their first
HD and in 5 of 10 patients who did not receive HBIG but were identical
in respect to all other conditions of treatment (X Yates: 6.57 — P <
0.02). In summary, (1) over a period of 42 months the incidence of
NANB H in a HBV-free unit has been 15%; (2) NANB H can only be
detected by a prospective search; (3) only 2/3 of patients previously had
received transfusions; (4) NANB had a chronic course in 2 of 3 patients;
(5) prophylactic HBIG significantly reduced the incidence of NANB H;
(6) markers of NANB virus were detected in 85% of the tested patients.
Amyloid P-component patterns in human nephropathies. C. Orfila, J.
Rakozoarivony, A. Segonds, J. M. Suc, INSERM U 133, CHU Ran-
gueil Toulouse, France. Amyloid P-component (AP) is a constant
constituent of all amyloid deposits, and it is present in glomerular and
vascular basement membranes of normal human tissues and in normal
human plasma. By immunofluorescence, the localization of AP staining
was studied in 69 renal biopsy specimens from patients with various
nephropathies and in three renal biopsy specimens of normal nontrans-
planted kidneys. A bright linear staining was observed along the
glomerular basement membranes (GBM) in normal kidneys. The inten-
sity varied from nearly negative to normally positive in minimal change
nephrotic syndrome. The staining was linear and faint along GBM in
patients with gross or microscopic hematuria associated with minor
glomerular abnormalities, in endocapillary proliferative glomerulone-
phritis (GN), and in IgA mesangial GN. Linear staining was associated
with rare granules along GBM in membranous GN. In type 1 mesangio-
capillary GN, different patterns were observed: granular and bright
along the GBM, in the mesangial stalk or faint in the vascular area. The
fluorescence was nearly negative along the GBM and in crescents in
diffuse crescentic GN. In only one case of focal glomeruloscierosis was
the fluorescence marked in the mesangial stalk. A bright linear staining
of GBM and nodules has been observed in diabetic nodular glomerulo-
sclerosis. In amyloidosis a characteristic nodular pattern was observed.
No case of AP staining was observed along tubular basement mem-
branes. The localization and intensity of AP along GBM and vascular
basement membranes seem to vary with the type of nephropathy. The
possible modification of the permeability of GBM related to a possible
modification of the electrical change of the filtration barrier can be
supposed.
Nephrotoxicity of iodinated contrast agents: Value of urinary gamma-
GT measurements. J. P. Pourra, R. Camare, M. At, J. Paraguette, J.
M. Dueymes, and J. J. Conté, Service de Nephrologie et d'Hemodia-
lyse; Service de Chirurgie Générale et Vasculaire; Laboratoire de
Biochimie 1-C.H. U. Toulouse-Purpan, Toulouse Cedex, France. Uri-
nary gamma-GT activity was studied before and after radiocontrast
procedure in 23 patients (14 men and 9 women) aged 65 13 years.
Patients with diabetes mellitus, myeloma, hyperuricemia, or renal
abnormality had been excluded, so all 23 patients had creatininemia
110 moles/1iter, serum uric acid 400 moles/liter, no proteinuria
and normal urinary sediment. Radiocontrast procedure was lower limb
arteriography using 80 ml of a triiodinated hydrosoluble contrast agent
(Angiografine®). No adverse reaction occurred during or after the
investigation; all patients received 500 ml isotonic Dextrose i.v. during
the 6 hr following angiography. Creatininemia was 84.8 14.7 p.moles/
liter before radiography; 87.6 12.3 p.moles/liter on day 1; 92.3 15.6
p.moles/liter on day 3 (not significant). Urinary output was 1.2 0.3 1/
24 hr before, and 1.6 0.8 1/24 hr after procedure (P < 0.05). Urinary
gamma-GT activity was 30.4 9.6 Ul/24 hr before and 65.0 48.8 UI
after angiography (P < 0.01). Urinary gamma-glutamyl-transferase
activity appears to be a good test for nephrotoxicity of iodinated
contrast agents. A rise in this activity has already been described
following tubular lesions in man and in the experimental animal,
observed after a radiocontrast procedure whereas kidney function tests
were unchanged. This measurement could be useful in studies of
proposed preventive measures.
Varying severity of glomerulonephritis (GN) in Balb/C, Swiss and, C3H
mice infected at birth with lymphocytic choriomeningitis (LCM) virus. P.
Ronco, D. Woodrow, Y. Rivière, J. C. Guillon, 1. Gresser, P. Verroust,
and L. Morel-Maroger. INSERM, Hôpital Tenon, Institut Pasteur,
Paris, France; Department of Experimental Pathology, Charing Cross
School of Medicine, London, United Kingdom, and JRSC, Villejuif,
France. Renal lesions due to neonatal infection with LCM virus were
studied in three different strains of mice known to produce different
amounts of interferon (IF). C3H mice, the best producers of IF, all died
within 12 days after inoculation and had striking ultrastructural lesions
of the glomeruli at day 8. By contrast Balb/C mice who produced the
lowest amount of IF had very mild early lesions, whereas an intermedi-
ate pattern was present in Swiss mice. Later on, circulating immune
complexes (CIC) were found in both Swiss and Balb/C mice, but they
were detected in greater amounts in the Swiss mice. Likewise, a severe
IC type glomerulonephritis was present both by light and immunofluo-
rescent microscopy in all the Swiss mice whereas Balb/C always had
mild lesions. These experiments show that the early lethal lesions
produced in mice infected neonatally by LCM virus are parallel to the
amount of circulating IF. Later in life, the severity of glomerular lesions
is related both to the amount of circulating immune complexes and to
that of IF. This suggests that IF plays a role in the glomerular handling
or trapping of CIC.
Hyperaluminemia test (HAT) by desferrioxamine (DFA) for the deter-
mination of tissue aluminum overload (TAO) in hemodialysis patients.
Aggravating factor of chronic infections by B and non-A, non-B virus. P.
Simon, P. Allain, Y. Mauras, K. S. Ang. Service de Nephrologie, CH
La Beauchée Saint Brieuc. Laboratoire de Pharmacologie, CHU
Angers, France. The aim of the study was to evaluate TAO by a HAT in
41 patients (22 men and 19 women) who were hemodialyzed during 4 to
168 months (mean: 49 months). HAT was performed by infusion of
DFA in doses of 2 g at the time of hemodialysis (HD). Plasma Al levels
(Alp g/liter) were measured before (Tl) and after (T2) infusion, then 48
to 72 hr after, before (T3) and after (T4) a new dialysis. Alp levels to T3
allowed measurement of Alp (T3 to TI) which was taken as an
indication of tissue Al stock and Alp (T3 to T4) which was unbound
filtrable Alp dialyzed. The total dose of Alp after chronic oral adminis-
tration of Al-containing phosphate binders (Al-PB), the duration of
treatment by HD with a dialysate with or without Al (<10 p.g/liter) and
the presence of chronic infection by B or non-A, non-B virus were
studied. (1) Alp TI and Alp (T3 to Ti) were <10 p.glliter in four
patients who were dialyzed during less than 6 months. (2) The highest
values of Alp (T3-Tl) (mean: 130.40 52.51) were found in 15 patients
who had chronic infections by B (10) and non-A, non-B (5) virus,
compared to 33.04 36.22 (P < 0.001) in other patients. In these there
was not a correlation between the total dose of Al-PB (R = 4.41 E-3),
the duration of treatment by HD (R = 0.05) and Alp (T3-Tl). (3) In 26
patients without viral infections who were treated during 4 to 42 months
with a dialysate without Al, positive correlations were found between
Alp TI (R = 0.43, P <0.05), Alp (T3 to TI) (R =0.80, P < 0.001) and
the total dose of Al-PB. On the contrary, there was not a correlation
with the duration of treatment by HD (R = 4.90 E-3 and R = 0.14). (4)
iAlp (T3 to T4) was 84.67 30.97 in patients with infections and 20.46
20.79 in patients without (P < 0.001). It was concluded that (1) after 6
months of HD, HAT provides a more precise measurement of TAO
than does predialytic Alp. (2) B and non-A, non-B viral chronic
infections are an aggravating factor of the overload. (3) The chronic oral
administration of Al PB is an etiologic factor of the overload. (4) The
unbound filtrable and chelated Alp was dialyzed. These findings should
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indicate DFA administration as therapy for patients at risk of Al
toxicity.
Hepatitis with Captopril treatment. J. P. Rycke!ynck, J. M. Batho, J.
Peny, D. Grach, P. Beuve-Mery. Service de Nephrologie et d'Hémo-
dialyse, CHRU Caen, France. A patient developed anicteric hepatitis
while being treated with Captopril (SQ 14 225). To date, only one case
with hepatic involvement during Captopril administration has been
reported. A 36-year-old woman with hypertension and end-stage renal
failure treated by hemodialysis received 50 mg Captopril four times
daily for 20 months. Every 3 months liver function tests were made;
these were normal until March 1981. At this time, the patient became
tired and complained of pruritus. On examination, there was no
abnormal sign. However, SGOT was 400 units• l (normal up to 18)
SGPT 550 units 1' (normal up to 21). Total bilirubin and alkaline
phosphatase were normal. Serum radioimmunoassays for hepatitis B
surface antigen (HBsAg) and for antibody to hepatitis A were negative,
as were complement fixing antibody titres to infective mononucleosis
and cytomegalovirus. A liver biopsy was performed which showed
lesions of hepatitis. Captopril therapy was discontinued and liver
disorders disappeared. Three weeks later, Captopril was re-introduced
in 50 mg twice daily; SGOT SGPT again rose. The results of this re-
introduction test allow the incrimination of this therapy in the genesis of
hepatic cytolysis.
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Clinical Relevance of N-acetyl-glucosaminidase determination in renal
allograft recipients immunosuppressed conventionally or by Cyclosporin
A. R. Loertscher, F. P. Brunner, G. Thiel. Nephrologie Abteilung,
Departement für Innere Medizin, Universität Base!, Switzerland. N-
acetyl-glucosaminidase (NAG) was monitored daily for 60 days in 25
recipients of an allograft between January and September 1981. Twelve
of these patients were treated by Cyclosponn A (CyA), 13 by conven-
tional immunosuppression with azathioprin and prednisone. NAG was
indicated as ratio NAG U/liter to urine creatinine mmoles/liter. The
purpose of these determinations was to evaluate NAG as an early
predictor of graft rejection and to estimate NAG excretion as indicator
for CyA toxicity. Rejection was assessed either clinically or by graft
biopsy (24 biopsies in 16 patients). CyA toxicity was estimated by
clinical signs, biochemical parameters (liver enzymes), CyA serum
trough level determinations, and graft biopsies. NAG excretion in both
groups did not correlate consistently with graft rejection. NAG determi-
nation did not help to establish this diagnosis. Different NAG profiles
showed the wide variation of NAG excretion. Only in single cases a
close correlation was found with postrenal obstruction and CyA serum
trough levels.
Fatal complications in kidney allotransplant recipients. G. Keusch, A.
Burgier, G. Uh!schmid, J. Briner, F. Largiader, U. Binswanger.
Medizinische und Chriurgische K!inik A, Inst itut fur Pathologie, Uni-
versitãtsspita! Zurich, Switzerland. At the university hospital of Zurich
523 patients (mean age 44 7 (SD) years, ranging from 7—60 years)
received 605 kidney allotransplants between November 1964 and Au-
gust 1980. During this period 193 deaths occurred and the causes of
death could be analyzed in 167 patients (86.5%) by hospital records and
autopsy findings. In 98 patients (58.7%) the kidney graft was still
functioning at the time of death. Forty-four percent of all deaths
occurred during the first 3 months following transplantation. Causes of
death included: Infections in 74 patients (44.3%); cardiovascular com-
plications in 30 patients (18%); cerebrovascular accidents in 13 patients
(7.8%); gastroduodenal complications in 11 patients (6.6%) and malig-
nancies in 14 patients (8.4%). Forty of 74 (54%) lethal infections
occurred during the first 3 months following transplantation. Bacterial
organisms (68% gram negative germs) accounted for 46%, viruses (73%
cytomegalo-viruses) for 27%, fungi for 15%, and parasitic organisms for
4% of the infections. The most frequently affected organs were the
lungs (73%), the gastrointestinal tract (43.2%), and the central nervous
system (23%). The incidence of viral and fungal infections showed a
maximum in the second and third post-transplant month. Lethal cere-
bro- and cardiovascular complications occurred either in the early
(within 3 months) or late (>2 years) post-transplant period. Malignan-
cies were a typical fatal complication in the late period following
transplantation including four fatal cases of solid lymphomas. Of the 11
patients with fatal gastrointestinal complications seven patients died as
a result of gastrointestinal ulcers. Data from this study showed that in
cadaveric kidney recipients infections were the leading cause of death,
occurring most frequently within the first 3 months and the predominate
site of infections were the lungs.
Renal replacement therapy in diabetics: A comparative analysis of
CAPD, hemodialysis, and cadaveric kidney transplantation. S. Peter, G.
Keusch, F. Bammatter, F. Largiader, U. Binswanger. Medizinische
und Chriurgische K!inik A, Universitdtsspital Zurich, Switzerland.
Thirty-four juvenile onset diabetic patients (mean age 39.4 10.1 (SD)
years) with end-stage renal failure were treated by the following renal
replacement therapy: CAPD in 13 patients (mean age 44.8 11.3
years), hemodialysis in 8 patients (39.8 9.8 years), and cadaveric
kidney transplantation in 13 patients (33.8 5.7 years). The follow-up
during 1.5 to 40.5 months (total patient-months 422.5) revealed 17
deaths. Nine deaths occurred at 6 months and 14 at 1 year, respectively.
The mortality and causes of death in the different treatment modalities
were as follows:
Mortality
at 6 months at 1 year at 2 years
CAPD
Hemodialysis
Transplantation
4/10 (40%)
2/8 (25%)
3/12 (25%)
5/6 (83%)
5/5 (100%)
4/10 (40%)
6/6
6/10
(100%)
—
(60%)
Causes of death
Infection
Cerebro- and cardio-
vasc. complications Others
4 1 1
0 5 —
2 3 1
CAPD
Hemodialysis
Transplantation
